AKTX

Akari Therapeutics plc ADR (0.01 USD)

0.13

USD

AKTX Earnings Reports

Positive Surprise Ratio

AKTX beat 8 of 17 last estimates.

47%

Next Report

Date of Next Report

Apr 13, 2026

Estimate for Q4 25 (Revenue/ EPS)

-$0.03

Implied change from Q-- -- (Revenue/ EPS)

Implied change from Q4 24 (Revenue/ EPS)

Akari Therapeutics plc ADR (0.01 USD) earnings per share and revenue

On --, AKTX reported earnings of -- USD per share (EPS) for -- --, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.

Looking ahead to Q4 25, 5 analysts forecast an EPS of -0.03 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Biofrontera Inc. Common Stock

Report Date

Mar 19, 2026 For Q4 25

Estimate

$0.19

Actual

$0.50

Surprise

+151.38%

Alvotech Ordinary Shares

Report Date

Mar 18, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.37

Surprise

-706.10%

Eton Pharmaceutcials, Inc. Common Stock

Report Date

Mar 19, 2026 For Q4 25

Estimate

$0.09

Actual

$0.05

Surprise

-45.53%

Cellectis S.A. - ADR

Report Date

Mar 19, 2026 For Q4 25

Estimate

-$0.26

Actual

-$0.26

Surprise

+1.78%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Mar 18, 2026 For Q4 25

Estimate

$0.00

Actual

-$0.07

Surprise

-1472.55%

Eledon Pharmaceuticals, Inc. Common Stock

Report Date

Mar 19, 2026 For Q4 25

Estimate

-$0.20

Actual

-$0.10

Surprise

+51.78%

Artiva Biotherapeutics, Inc. Common Stock

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$0.84

Actual

Surprise

Milestone Pharmaceuticals Inc. Common Shares

Report Date

Mar 20, 2026 For Q4 25

Estimate

-$0.16

Actual

-$0.16

Surprise

+1.96%

Spruce Biosciences, Inc. Common Stock

Report Date

Apr 13, 2026 For Q4 25

Estimate

-$8.14

Actual

Surprise

FAQ

What were Akari Therapeutics plc ADR (0.01 USD)'s earnings and revenue for the latest quarter Q-- --?

For Q-- --, Akari Therapeutics plc ADR (0.01 USD) reported EPS of --, Inline estimates by --, and revenue of --, -- -- expectations.

How did the market react to Akari Therapeutics plc ADR (0.01 USD)'s Q-- -- earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is Akari Therapeutics plc ADR (0.01 USD) expected to report next?

The next earning report is scheduled for Apr 13, 2026.

What are the forecasts for Akari Therapeutics plc ADR (0.01 USD)'s next earnings report?

Based on 5 analysts, Akari Therapeutics plc ADR (0.01 USD) is expected to report EPS of -$0.03 and revenue of -- for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.